Loading insider details...
Beta
Latest Form 4 (May 11, 2026): Purchase of 507,407 ATRA shares, $4.74M.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| May 11, 2026 | Atara Biotherapeutics, Inc. (ATRA) | Purchase | 507,407 | $4.74M |
| Apr 22, 2026 | First Tracks Biotherapeutics, Inc. (TRAX) | Sale | 4,705,575 | $65.00M |
| Jan 13, 2026 | Aktis Oncology, Inc. (AKTS) | Conversion | 2,270,879 | n/a |
| Jul 30, 2025 | Adaptimmune Therapeutics PLC (ADAP) | Sale | 33,931,740 | $3.82M |
| Jun 27, 2025 | Zymeworks Inc. (ZYME) | In-the-Money Exercise | 5,086,480 | $508.65 |
| May 19, 2025 | Zymeworks Inc. (ZYME) | Purchase | 49,502 | $565.8K |
| May 6, 2025 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Sale | 3,317,938 | $27.74M |
| Apr 18, 2025 | Zymeworks Inc. (ZYME) | Purchase | 73,953 | $825.6K |
| Apr 7, 2025 | Zymeworks Inc. (ZYME) | Purchase | 120,770 | $1.43M |
| Apr 2, 2025 | Zymeworks Inc. (ZYME) | Purchase | 4,397 | $51.7K |